Eucalyptol
Expectorants
Sold as Antispetic · Antiseptic · Tartar control · Original Antiseptic · Tartar control plus
- Drug class
- Expectorants
- Availability
- Over-the-counter
- Routes
- Oral, Rectal
- Markets covered
- 2
- Products on record
- 18
- FDA reports (12 mo)
- 64
Overview
Plain-language summary, compiled from the cited regulatory records
Eucalyptol is an active ingredient classified as an expectorant [1]. Its approved use is to help control plaque, which can lead to gingivitis [1].
This ingredient is available in the market under various brand names, including Antispetic, Tartar control plus, and Original Antiseptic [1]. In the past 12 months, there have been 64 adverse event reports associated with products containing eucalyptol [2]. The most frequently reported reactions include claims of the drug being ineffective, dyspnoea, product use in unapproved indications, arthralgia, and malaise [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 16 | April 14, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
USUnited States· FDA
16 products
Uses
Use helps control plaque that leads to gingivitis
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Sources & citations
- [1]FDA DailyMed · 02ffe892-732b-47… · revised January 29, 2026 [PDF]
- [2]Health Canada (DPD) · 00319716 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.